-
4
-
-
84898491795
-
Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: A randomized controlled trial
-
Yokoyama S, Takahashi S, Kawakami Y, Hayes CN, Kohno H, Kohno H, Tsuji K, et al. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. J Viral Hepat 2014; 21: 348-56.
-
(2014)
J Viral Hepat
, vol.21
, pp. 348-356
-
-
Yokoyama, S.1
Takahashi, S.2
Kawakami, Y.3
Hayes, C.N.4
Kohno, H.5
Kohno, H.6
Tsuji, K.7
-
5
-
-
84894816994
-
Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterfer on/ribavirin obviates a protease inhibitor
-
Pearlman BL, Ehleben C. Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterfer on/ribavirin obviates a protease inhibitor. Hepatology 2014; 59: 71-7.
-
(2014)
Hepatology
, vol.59
, pp. 71-77
-
-
Pearlman, B.L.1
Ehleben, C.2
-
6
-
-
84891832915
-
Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: A meta-analysis
-
Park C, Jiang S, Lawson KA. Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis. J Clin Pharm Ther 2014; 39: 14-24.
-
(2014)
J Clin Pharm Ther
, vol.39
, pp. 14-24
-
-
Park, C.1
Jiang, S.2
Lawson, K.A.3
-
7
-
-
84899651307
-
Peg-Interferon Plus Ribavirin with or without Boceprevir or Telaprevir for HCV Genotype 1: A Meta-Analysis on the Role of Response Predictors
-
Coppola N, Pisaturo M, Sagnelli C, Sagnelli E, Angelillo IF. Peg-Interferon Plus Ribavirin with or without Boceprevir or Telaprevir for HCV Genotype 1: A Meta-Analysis on the Role of Response Predictors. PLoS One 2014; 9: e94542.
-
(2014)
PLoS One
, vol.9
-
-
Coppola, N.1
Pisaturo, M.2
Sagnelli, C.3
Sagnelli, E.4
Angelillo, I.F.5
-
8
-
-
84872565980
-
Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: A systematic review
-
Chou R, Hartung D, Rahman B, Wasson N, Cottrell EB, Fu R. Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Ann Intern Med 2013; 158: 114-23.
-
(2013)
Ann Intern Med
, vol.158
, pp. 114-123
-
-
Chou, R.1
Hartung, D.2
Rahman, B.3
Wasson, N.4
Cottrell, E.B.5
Fu, R.6
-
9
-
-
84904907334
-
Response-Guided Therapy in Patients with Genotype 1 HCV: Current Status and Future Prospects
-
Lawitz EJ, Membreno FE. Response-Guided Therapy in Patients with Genotype 1 HCV: Current Status and Future Prospects. J Gastroenterol Hepatol 2014; 29 (8): 1574-81 doi: 10.1111/jgh.12632.
-
(2014)
J Gastroenterol Hepatol
, vol.29
, Issue.8
, pp. 1574-1581
-
-
Lawitz, E.J.1
Membreno, F.E.2
-
10
-
-
33646590308
-
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy
-
Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, Ferenci P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43: 954-60.
-
(2006)
Hepatology
, vol.43
, pp. 954-960
-
-
Jensen, D.M.1
Morgan, T.R.2
Marcellin, P.3
Pockros, P.J.4
Reddy, K.R.5
Hadziyannis, S.J.6
Ferenci, P.7
-
11
-
-
84859001212
-
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
-
Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
-
(2011)
BMJ
, vol.343
-
-
Higgins, J.P.1
Altman, D.G.2
Gotzsche, P.C.3
Juni, P.4
Moher, D.5
Oxman, A.D.6
Savovic, J.7
-
13
-
-
84859984959
-
-
Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark
-
Thorlund K. User manual for trial sequential analysis (TSA). Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark; 2011, p. 1-115.
-
(2011)
User manual for trial sequential analysis (TSA).
, pp. 1-115
-
-
Thorlund, K.1
-
14
-
-
65449171953
-
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection
-
Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-50.
-
(2009)
N Engl J Med
, vol.360
, pp. 1839-1850
-
-
Hezode, C.1
Forestier, N.2
Dusheiko, G.3
Ferenci, P.4
Pol, S.5
Goeser, T.6
Bronowicki, J.P.7
-
15
-
-
77950817619
-
Telaprevir for previously treated chronic HCV infection
-
McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-303.
-
(2010)
N Engl J Med
, vol.362
, pp. 1292-1303
-
-
McHutchison, J.G.1
Manns, M.P.2
Muir, A.J.3
Terrault, N.A.4
Jacobson, I.M.5
Afdhal, N.H.6
Heathcote, E.J.7
-
16
-
-
65449152185
-
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection
-
McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-38.
-
(2009)
N Engl J Med
, vol.360
, pp. 1827-1838
-
-
McHutchison, J.G.1
Everson, G.T.2
Gordon, S.C.3
Jacobson, I.M.4
Sulkowski, M.5
Kauffman, R.6
McNair, L.7
-
17
-
-
84885475374
-
Telaprevir in Combination with Peginterferon Alfa- 2a/Ribavirin in HCV/HIV Co-infected Patients: SVR24 Final Study Results
-
Sulkowski M. Telaprevir in Combination with Peginterferon Alfa- 2a/Ribavirin in HCV/HIV Co-infected Patients: SVR24 Final Study Results. Hepatology 2012; 56: 1144A.
-
(2012)
Hepatology
, vol.56
, pp. 1144A
-
-
Sulkowski, M.1
-
18
-
-
79953176289
-
Boceprevir for previously treated chronic HCV genotype 1 infection
-
Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
-
(2011)
N Engl J Med
, vol.364
, pp. 1207-1217
-
-
Bacon, B.R.1
Gordon, S.C.2
Lawitz, E.3
Marcellin, P.4
Vierling, J.M.5
Zeuzem, S.6
Poordad, F.7
-
19
-
-
79953173221
-
Boceprevir for untreated chronic HCV genotype 1 infection
-
Poordad F, McCone J, Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
-
(2011)
N Engl J Med
, vol.364
, pp. 1195-1206
-
-
Poordad, F.1
McCone, J.2
Bacon, B.R.3
Bruno, S.4
Manns, M.P.5
Sulkowski, M.S.6
Jacobson, I.M.7
-
20
-
-
79959438789
-
Telaprevir for previously untreated chronic hepatitis C virus infection
-
Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
-
(2011)
N Engl J Med
, vol.364
, pp. 2405-2416
-
-
Jacobson, I.M.1
McHutchison, J.G.2
Dusheiko, G.3
Di Bisceglie, A.M.4
Reddy, K.R.5
Bzowej, N.H.6
Marcellin, P.7
-
21
-
-
80052826527
-
Response-guided telaprevir combination treatment for hepatitis C virus infection
-
Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-24.
-
(2011)
N Engl J Med
, vol.365
, pp. 1014-1024
-
-
Sherman, K.E.1
Flamm, S.L.2
Afdhal, N.H.3
Nelson, D.R.4
Sulkowski, M.S.5
Everson, G.T.6
Fried, M.W.7
-
22
-
-
79959381354
-
Telaprevir for retreatment of HCV infection
-
Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
-
(2011)
N Engl J Med
, vol.364
, pp. 2417-2428
-
-
Zeuzem, S.1
Andreone, P.2
Pol, S.3
Lawitz, E.4
Diago, M.5
Roberts, S.6
Focaccia, R.7
-
23
-
-
84879795434
-
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: A randomised, double-blind, controlled phase 2 trial
-
Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, Rivero A, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013; 13: 597-605.
-
(2013)
Lancet Infect Dis
, vol.13
, pp. 597-605
-
-
Sulkowski, M.1
Pol, S.2
Mallolas, J.3
Fainboim, H.4
Cooper, C.5
Slim, J.6
Rivero, A.7
-
24
-
-
83555163652
-
Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan
-
Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012; 56: 78-84.
-
(2012)
J Hepatol
, vol.56
, pp. 78-84
-
-
Kumada, H.1
Toyota, J.2
Okanoue, T.3
Chayama, K.4
Tsubouchi, H.5
Hayashi, N.6
-
25
-
-
84870947010
-
Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection
-
quiz e85
-
Flamm SL, Lawitz E, Jacobson I, Bourliere M, Hezode C, Vierling JM, Bacon BR, et al. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin Gastroenterol Hepatol 2013; 11: 81-87, e84; quiz e85.
-
(2013)
Clin Gastroenterol Hepatol
, vol.11
-
-
Flamm, S.L.1
Lawitz, E.2
Jacobson, I.3
Bourliere, M.4
Hezode, C.5
Vierling, J.M.6
Bacon, B.R.7
-
26
-
-
84879799809
-
Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: A randomized trial
-
Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, Gharakhanian S, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013; 159: 86-96.
-
(2013)
Ann Intern Med
, vol.159
, pp. 86-96
-
-
Sulkowski, M.S.1
Sherman, K.E.2
Dieterich, D.T.3
Bsharat, M.4
Mahnke, L.5
Rockstroh, J.K.6
Gharakhanian, S.7
-
27
-
-
84890558343
-
Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: A multicenter experience
-
Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, Pageaux GP, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 2014; 60: 78-86.
-
(2014)
J Hepatol
, vol.60
, pp. 78-86
-
-
Coilly, A.1
Roche, B.2
Dumortier, J.3
Leroy, V.4
Botta-Fridlund, D.5
Radenne, S.6
Pageaux, G.P.7
-
28
-
-
84882908504
-
Triple therapy in treatmentexperienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890
-
Hezode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, de Ledinghen V, et al. Triple therapy in treatmentexperienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 2013; 59: 434-41.
-
(2013)
J Hepatol
, vol.59
, pp. 434-441
-
-
Hezode, C.1
Fontaine, H.2
Dorival, C.3
Larrey, D.4
Zoulim, F.5
Canva, V.6
de Ledinghen, V.7
-
29
-
-
84894134567
-
New triple therapy for chronic hepatitis C: Real life clinical experience in a community setting
-
Akiyama MJ, Piotrowski JI, Roytman MM, Chan SM, Hong LK, Huddleston L, Trujillo R, et al. New triple therapy for chronic hepatitis C: real life clinical experience in a community setting. Hawaii J Med Public Health 2013; 72: 6-13.
-
(2013)
Hawaii J Med Public Health
, vol.72
, pp. 6-13
-
-
Akiyama, M.J.1
Piotrowski, J.I.2
Roytman, M.M.3
Chan, S.M.4
Hong, L.K.5
Huddleston, L.6
Trujillo, R.7
-
30
-
-
84889646106
-
Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort
-
Backus LI, Belperio PS, Shahoumian TA, Cheung R, Mole LA. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. Aliment Pharmacol Ther 2014; 39: 93-103.
-
(2014)
Aliment Pharmacol Ther
, vol.39
, pp. 93-103
-
-
Backus, L.I.1
Belperio, P.S.2
Shahoumian, T.A.3
Cheung, R.4
Mole, L.A.5
-
31
-
-
84918769794
-
The Real Life Experience With the Development and Management of Anemia in the Era of Protease Inhibitors for Chronic Hepatitis C Infection
-
Singh G. The Real Life Experience With the Development and Management of Anemia in the Era of Protease Inhibitors for Chronic Hepatitis C Infection. Gastroenterology 2013; 144: S-1136.
-
(2013)
Gastroenterology
, vol.144
-
-
Singh, G.1
-
32
-
-
80053477775
-
Anemia during treatment with peginterferon alfa-2b/ ribavirin with or without boceprevir is associated with higher svr rates: Analysis of previously untreated and previous-treatment-failure patients
-
Sulkowski M. Anemia during treatment with peginterferon alfa-2b/ ribavirin with or without boceprevir is associated with higher svr rates: analysis of previously untreated and previous-treatment-failure patients. J Hepatol 2011; 54: 594.
-
(2011)
J Hepatol
, vol.54
, pp. 594
-
-
Sulkowski, M.1
-
33
-
-
84898467864
-
Analysis of the optimal TVR dose per weight judging from anemia during PEG-IFN/RBV/TVR combination therapy
-
Karino Y. Analysis of the optimal TVR dose per weight judging from anemia during PEG-IFN/RBV/TVR combination therapy. J Hepatol 2013; 58: S338.
-
(2013)
J Hepatol
, vol.58
, pp. S338
-
-
Karino, Y.1
-
34
-
-
84891727750
-
Timing and magnitude of ribavirin dose reduction (RBV DR) do not impact sustained virologic response (SVR) rates with boceprevir (BOC) + peginterferon alfa-2b/ribavirin (P/RBV) in the Anemia Management Study in chronic HCV genotype 1 patients
-
Lawitz E. Timing and magnitude of ribavirin dose reduction (RBV DR) do not impact sustained virologic response (SVR) rates with boceprevir (BOC) + peginterferon alfa-2b/ribavirin (P/RBV) in the Anemia Management Study in chronic HCV genotype 1 patients. Hepatology 2012; 56: 1144A.
-
(2012)
Hepatology
, vol.56
, pp. 1144A
-
-
Lawitz, E.1
-
35
-
-
84918818436
-
Is Week 1 (W1) and Week 2 (W2) Monitoring Helpful in Patients Treated for Chronic Hepatitis C With Pegylated Interferon, Ribavirin and a Protease Inhibitor
-
Purohit T. Is Week 1 (W1) and Week 2 (W2) Monitoring Helpful in Patients Treated for Chronic Hepatitis C With Pegylated Interferon, Ribavirin and a Protease Inhibitor. Gastroenterology 2013; 144: S983-S984.
-
(2013)
Gastroenterology
, vol.144
, pp. S983-S984
-
-
Purohit, T.1
-
36
-
-
84918773244
-
Serum Interleukin-6 levels during treatment correlate with resistance to Telaprevir based triple therapy in chronic hepatitis C
-
Asahina Y. Serum Interleukin-6 levels during treatment correlate with resistance to Telaprevir based triple therapy in chronic hepatitis C. J Hepatol 2013; 58: S321.
-
(2013)
J Hepatol
, vol.58
, pp. S321
-
-
Asahina, Y.1
-
37
-
-
84918837618
-
Impact of the viral kinetics of chronic hepatitis C patients treated with telaprevir in combination with Pegylated Interferon A2b and Ribavirin
-
Ogawa E. Impact of the viral kinetics of chronic hepatitis C patients treated with telaprevir in combination with Pegylated Interferon A2b and Ribavirin. J Hepatol 2013; 58: S-632.
-
(2013)
J Hepatol
, vol.58
-
-
Ogawa, E.1
-
38
-
-
82755182674
-
Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir
-
Susser S, Vermehren J, Forestier N, Welker MW, Grigorian N, Fuller C, Perner D, et al. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. J Clin Virol 2011; 52: 321-7.
-
(2011)
J Clin Virol
, vol.52
, pp. 321-327
-
-
Susser, S.1
Vermehren, J.2
Forestier, N.3
Welker, M.W.4
Grigorian, N.5
Fuller, C.6
Perner, D.7
-
39
-
-
84873598160
-
Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: A prospective longitudinal study
-
Hoffmann L, Ramos JA, Souza EV, Araujo Ramos AL, Villela- Nogueira CA, Urmenyi TP, Tanuri A, et al. Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study. Virol J 2013; 10: 57.
-
(2013)
Virol J
, vol.10
, pp. 57
-
-
Hoffmann, L.1
Ramos, J.A.2
Souza, E.V.3
Araujo Ramos, A.L.4
Villela-Nogueira, C.A.5
Urmenyi, T.P.6
Tanuri, A.7
-
40
-
-
84855223355
-
Long-Term Follow-Up Of Chronic Hepatitis C Infected Patients Treated With Telaprevir: Evaluation Of Persistence Of Resistant Variants By Ultra-Deep Sequencing
-
Thomas XV. Long-Term Follow-Up Of Chronic Hepatitis C Infected Patients Treated With Telaprevir: Evaluation Of Persistence Of Resistant Variants By Ultra-Deep Sequencing. J Hepatol 2011; 54: S490-S491.
-
(2011)
J Hepatol
, vol.54
, pp. S490-S491
-
-
Thomas, X.V.1
-
41
-
-
84918825148
-
Dynamics Of Hcv Quasispecies During Telaprevir Treatment Dissected Using Ultra-Deep Pyrosequencing: Treatment Failure In 100% Of Genotype 1a Patients
-
Pinson P. Dynamics Of Hcv Quasispecies During Telaprevir Treatment Dissected Using Ultra-Deep Pyrosequencing: Treatment Failure In 100% Of Genotype 1a Patients. J Hepatol 2012; 56: S614.
-
(2012)
J Hepatol
, vol.56
, pp. S614
-
-
Pinson, P.1
-
42
-
-
84918828884
-
Cross-sectional Assessment of Telaprevir and Boceprevir resistance-associated mutations of 500 clinical samples submitted for HCV NS3/4A protease inhibitor drug resistance testing in the US
-
Volpe JM. Cross-sectional Assessment of Telaprevir and Boceprevir resistance-associated mutations of 500 clinical samples submitted for HCV NS3/4A protease inhibitor drug resistance testing in the US. Hepatology 2012; 54: 1144A.
-
(2012)
Hepatology
, vol.54
, pp. 1144A
-
-
Volpe, J.M.1
-
43
-
-
84918829321
-
Timing And Characteristics Of Drug Resistance Mutations (Drms) In Chronic Hepatitis C Patients During And After Treatment With Protease Inhibitor Therapy At A Single Centre
-
Velazquez C. Timing And Characteristics Of Drug Resistance Mutations (Drms) In Chronic Hepatitis C Patients During And After Treatment With Protease Inhibitor Therapy At A Single Centre. J Hepatol 2013; 58: S632.
-
(2013)
J Hepatol
, vol.58
, pp. S632
-
-
Velazquez, C.1
-
44
-
-
84918780701
-
Amino Acid Change In The Positions Associated With Protease Inhibitors Resistance Is Less Frequent In Genotype 3 Than In Genotype 1 Hcv Natural Strain
-
Messina E. Amino Acid Change In The Positions Associated With Protease Inhibitors Resistance Is Less Frequent In Genotype 3 Than In Genotype 1 Hcv Natural Strain. J Hepatol 2013; 58: S632.
-
(2013)
J Hepatol
, vol.58
, pp. S632
-
-
Messina, E.1
-
45
-
-
84918835309
-
Clinical implications of baseline population sequencing of the NS3 protease in HCV-1 partial or null-responders to Peg-interferon/ribavirin
-
Galmozzi. Clinical implications of baseline population sequencing of the NS3 protease in HCV-1 partial or null-responders to Peg-interferon/ribavirin. Dig Liver Dis 2013; 45: S54.
-
(2013)
Dig Liver Dis
, vol.45
, pp. S54
-
-
Galmozzi1
-
46
-
-
84918817335
-
HCV Kinetics And Quasispecies Evolution Within The First Hours Of Telaprevir-Based Triple Therapy In Previously Treated HCV-Patients
-
Cento V. HCV Kinetics And Quasispecies Evolution Within The First Hours Of Telaprevir-Based Triple Therapy In Previously Treated HCV-Patients. J Hepatol 2013; 58: S632.
-
(2013)
J Hepatol
, vol.58
, pp. S632
-
-
Cento, V.1
-
47
-
-
84918817335
-
Correlation Of Early Detection Of Hcv Ns3-Resistance And Virological Failure In Patients Treated With Triple Therapy Including Telaprevir Or Boceprevir
-
Cento V. Correlation Of Early Detection Of Hcv Ns3-Resistance And Virological Failure In Patients Treated With Triple Therapy Including Telaprevir Or Boceprevir. J Hepatol 2013; 58: S632.
-
(2013)
J Hepatol
, vol.58
, pp. S632
-
-
Cento, V.1
-
48
-
-
84871853264
-
Host genetic variants in the pathogenesis of hepatitis C
-
Rau M, Baur K, Geier A. Host genetic variants in the pathogenesis of hepatitis C. Viruses 2012; 4: 3281-302.
-
(2012)
Viruses
, vol.4
, pp. 3281-3302
-
-
Rau, M.1
Baur, K.2
Geier, A.3
-
49
-
-
79958830099
-
Hepatitis C virus resistance to protease inhibitors
-
Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011; 55: 192-206.
-
(2011)
J Hepatol
, vol.55
, pp. 192-206
-
-
Halfon, P.1
Locarnini, S.2
-
50
-
-
84884501841
-
Natural NS3 resistance polymorphisms occur frequently prior to treatment in HIV-positive patients with acute hepatitis C
-
Leggewie M, Sreenu VB, Abdelrahman T, Leitch EC, Wilkie GS, Klymenko T, Muir D, et al. Natural NS3 resistance polymorphisms occur frequently prior to treatment in HIV-positive patients with acute hepatitis C. AIDS 2013; 27: 2485-8.
-
(2013)
AIDS
, vol.27
, pp. 2485-2488
-
-
Leggewie, M.1
Sreenu, V.B.2
Abdelrahman, T.3
Leitch, E.C.4
Wilkie, G.S.5
Klymenko, T.6
Muir, D.7
|